Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Company Announcement, Helsinki, 6 March 2025 at 12:30 PM (EET)
Nexstim Plc: Managers’ Transactions, Karvinen
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows:
Person subject to the notification requirement
Name: Mikko Karvinen
Position: Chief Executive Officer
Issuer: Nexstim Oyj
LEI: 743700S7ZI0LNMHZ6Y27
Notification type: INITIAL NOTIFICATION
Reference number: 98963/5/6
____________________________________________
Transaction date: 2025-03-03
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000506811
Nature of transaction: SUBSCRIPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 12500 Unit price: 2 EUR
(2): Volume: 27 Unit price: 5 EUR
(3): Volume: 27 Unit price: 1 EUR
Aggregated transactions (3):
Volume: 12554 Volume weighted average price: 2.0043 EUR
____________________________________________
Transaction date: 2025-03-05
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000506811
Nature of transaction: DISPOSAL
Transaction details
(1): Volume: 45 Unit price: 8.3 EUR
(2): Volume: 97 Unit price: 8.26 EUR
(3): Volume: 593 Unit price: 8.16 EUR
(4): Volume: 750 Unit price: 8.2 EUR
(5): Volume: 328 Unit price: 8.16 EUR
(6): Volume: 422 Unit price: 8.14 EUR
(7): Volume: 750 Unit price: 8.2 EUR
(8): Volume: 750 Unit price: 8.16 EUR
Aggregated transactions (8):
Volume: 3735 Volume weighted average price: 8.17809 EUR
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
The Company’s Certified Advisor is Carnegie Investment Bank AB (publ).
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com